Immune checkpoint inhibitors may impact ovarian function as measured by anti-Müllerian hormone (AMH) levels, which has been seen in melanoma patients.78 However, the decline in AMH appears less severe than that seen with chemotherapy. Here, AMH is linked to melanoma.